STSA Satsuma Pharmaceuticals

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference 

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference 

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional details below:

Dates:Tuesday – Thursday, December 1st-3rd 2020
Format:One-on-one meetings with Satsuma Management
Location:Virtual Meetings

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit .

INVESTOR AND CORPORATE CONTACTS:

Corey Davis, PhD

LifeSci Advisors, LLC

Tom O’Neil, Chief Financial Officer

Satsuma Pharmaceuticals, Inc.

 



EN
24/11/2020

Underlying

STSASatsuma Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Satsuma Pharmaceuticals

 PRESS RELEASE
Free
STSA Satsuma Pharmac...

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 fo...

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), ...

June 15, 2023 1 EN
 PRESS RELEASE
Free
STSA Satsuma Pharmac...

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for ...

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds witho...

May 18, 2023 1 EN
 PRESS RELEASE
Free
STSA Satsuma Pharmac...

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th...

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- . (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person f...

April 21, 2023 1 EN
 PRESS RELEASE
Free
STSA Satsuma Pharmac...

SNBL to Acquire Satsuma Pharmaceuticals

SNBL to Acquire Satsuma Pharmaceuticals Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma’s Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- . (“Satsuma”) (Nasd...

April 16, 2023 1 EN
 PRESS RELEASE
Free
STSA Satsuma Pharmac...

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Fina...

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects - - Submitted STS101 New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in March 2023 - - Company seeking to maximize value for stockholders via strategic transaction - - ~36% workforce reduction to be implemented effective March 31, 2023 - - $52.5 million in cash, cash equi...

March 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch